| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2013: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Research Abstract |
Here we show the function of alpha-synuclein(SNCA) in the glucose metabolism, which is a susceptible gene for Parkinson disease. In a transversal study in Japanese population, we found that serum SNCA was strongly inversely correlated with elevated seric insulin resistance indicators. Additionally, in SNCA knock-out mice only glucose metabolism is impaired in glucose and insulin response during dietary-induced insulin resistance. In vitro, treatment of recombinant SNCA activates PI3K/Akt pathway through Gab1 activation, independently of insulin receptor activation, leading to glucose uptake in 3T3-L1 cells. Also in vivo, injection of SNCA activates Gab1-Akt-glucose uptake pathway in adipose tissue and muscle thereby promoting glucose utilization in mice. Moreover, during insulin resistance, SNCA treatment decreased blood glucose levels thus recovering glucose utilization in tissues. These findings suggest serum SNCA potential for prevention or treatment against insulin resistance.
|
